Does Medicare Cover Zepbound? Insurance Guide 2026

Bold opening In 2026, Medicare beneficiaries seeking Zepbound—a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management—face complex coverage rules. While Zepbound (tirzepatide) has shown superior efficacy in clinical trials compared to older GLP-1 drugs, Medicare’s coverage depends on the indication, plan type, and prior authorization requirements. This guide breaks down Medicare’s stance on Zepbound, out-of-pocket costs, appeals processes, and alternatives if coverage is denied.

Does Medicare Cover Zepbound for Diabetes?

Medicare may cover Zepbound for type 2 diabetes under Part D (prescription drug plans) or Medicare Advantage (Part C) plans with drug coverage, but not under Original Medicare (Parts A and B). The 2026 Medicare Coverage Gap Discount Program includes Zepbound as a Tier 3 or 4 drug, meaning beneficiaries typically pay 25–33% coinsurance after meeting the deductible.

Evidence-based criteria for coverage:

• FDA approval: Zepbound was approved in 2022 for glycemic control in adults with type 2 diabetes (A1C ≥7%) when used alongside diet and exercise.
• Clinical guidelines: The American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) recommend GLP-1/GIP agonists like Zepbound as second-line therapy after metformin failure or for patients with cardiovascular disease.
• Medicare’s stance: While Zepbound is not excluded under the Part D protected classes (unlike weight-loss drugs), plans may require step therapy (e.g., trying metformin or sulfonylureas first) or prior authorization.

Key limitation: If prescribed solely for weight loss, Medicare explicitly excludes coverage under Section 1862(a)(17) of the Social Security Act, which bars payment for obesity treatments unless part of a broader diabetes or cardiovascular management plan.

Does Medicare Cover Zepbound for Weight Loss?

Medicare does not cover Zepbound for weight loss alone, even though the FDA approved it in 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities. This exclusion stems from the Medicare Modernization Act of 2003, which prohibits coverage for “agents when used for anorexia, weight loss, or weight gain.”

Workarounds for partial coverage:

1. Diabetes comorbidity: If a patient has type 2 diabetes and obesity, Zepbound may be covered under the diabetes indication, with weight loss as a secondary benefit.
2. Cardiovascular risk: Emerging data from the SURMOUNT-4 trial (2024) showed Zepbound reduced major adverse cardiovascular events (MACE) by 20% in obese patients with preexisting CVD. Medicare may approve Zepbound if prescribed to mitigate cardiovascular risk, though this is not yet a standard policy.
3. Medicare Advantage plans: Some Part C plans offer supplemental benefits for obesity management, including Zepbound, but this varies by insurer (e.g., UnitedHealthcare, Humana).

Cost without coverage: Without Medicare reimbursement, Zepbound costs $1,060–$1,350 per month out-of-pocket, though manufacturer coupons (e.g., Eli Lilly’s Zepbound Savings Card) may reduce costs to $25/month for 12 months for commercially insured patients (not applicable to Medicare).

How Much Does Zepbound Cost With Medicare?

The cost of Zepbound with Medicare depends on the Part D plan’s formulary tier, deductible, and phase of coverage (initial, gap, or catastrophic). In 2026, Zepbound is typically classified as a Tier 4 (preferred brand) or Tier 5 (non-preferred brand) drug, with the following estimated costs:

Key factors affecting cost:

• Plan formularies: Some Part D plans (e.g., SilverScript Choice) cover Zepbound at Tier 3 with a $47 copay, while others (e.g., Aetna Medicare Rx) place it at Tier 5 with 33% coinsurance.
• Manufacturer assistance: Eli Lilly’s Zepbound Savings Card is not valid for Medicare beneficiaries, but the Lilly Cares Foundation offers free medication to patients with incomes ≤300% of the federal poverty level ($45,000/year for individuals in 2026).
• Mail-order pharmacies: Using CVS Caremark or Express Scripts may reduce costs by 10–15% compared to retail pharmacies.

Pro tip: Use Medicare’s Plan Finder Tool to compare Zepbound costs across Part D plans in your area.

Zepbound Prior Authorization for Medicare

Medicare Part D plans routinely require prior authorization (PA) for Zepbound to ensure medical necessity and cost control. The PA process typically involves:

1. Prescriber documentation:

   • For diabetes: Proof of A1C ≥7% despite metformin ± other oral agents, or intolerance to alternatives (e.g., GLP-1s like Ozempic or Victoza).
   • For cardiovascular risk: Documentation of obesity (BMI ≥30) with hypertension, dyslipidemia, or prior MACE.
   • For weight loss (if applicable): Evidence of failed lifestyle interventions (e.g., dietitian referrals, exercise programs).

2. Step therapy requirements:

   • Plans may require patients to try metformin, SGLT2 inhibitors (e.g., Jardiance), or older GLP-1s (e.g., Ozempic) before approving Zepbound.
   • Exception: Patients with contraindications (e.g., pancreatitis, medullary thyroid cancer) may bypass step therapy.

3. Appeal process:

   • If denied, prescribers can submit a redetermination request with additional clinical data (e.g., SURPASS trial results showing Zepbound’s superiority over semaglutide in A1C reduction).
   • Independent Review Entity (IRE): If the plan upholds the denial, patients can escalate to Maximus Federal Services, which overturns ~40% of Part D denials.

Average PA processing time: 3–14 days, though urgent requests (e.g., uncontrolled diabetes) may be expedited in 24–72 hours.

How to Get Medicare to Cover Zepbound

To maximize the chances of Medicare covering Zepbound, follow these evidence-based strategies:

1. Align with FDA-approved indications:

   • Prescribe Zepbound only for type 2 diabetes or cardiovascular risk reduction (not primary weight loss). Use ICD-10 codes E11.65 (diabetes with hyperglycemia) or Z68.41 (BMI ≥40) to justify medical necessity.

2. Leverage clinical guidelines:

   • Cite ADA 2026 Standards of Care, which recommend Zepbound for patients with A1C >9% or CVD risk factors.
   • Highlight SURPASS-2 trial data (2021), where Zepbound reduced A1C by 2.3% vs. 1.9% with semaglutide at 40 weeks.

3. Document failed alternatives:

   • Record prior use of metformin, sulfonylureas, or SGLT2 inhibitors with inadequate response or intolerance.
   • Note contraindications to GLP-1s (e.g., gastroparesis, history of pancreatitis).

4. Work with a Medicare-savvy pharmacist:

   • Pharmacists can help navigate formularies, submit PA requests, and identify lower-cost alternatives (e.g., compounded tirzepatide if Zepbound is denied).

5. Consider Medicare Advantage:

   • Some Part C plans (e.g., Kaiser Permanente, SCAN Health Plan) cover Zepbound for obesity if bundled with diabetes or CVD management programs.

Pro tip: Use Medicare’s “Coverage with Evidence Development” (CED) pathway for off-label uses. For example, if prescribing Zepbound for NAFLD (non-alcoholic fatty liver disease), submit liver enzyme trends (ALT/AST) to support coverage.

What to Do If Medicare Denies Zepbound

If Medicare denies Zepbound, patients have four appeal levels:

1. Redetermination (Level 1):

   • Submit a written request to the Part D plan within 60 days of denial.
   • Include:
     • Physician’s letter detailing medical necessity (e.g., “Patient’s A1C remains at 9.2% despite maximum-dose metformin”).
     • Lab results (e.g., A1C, lipid panel, BMI).
     • Peer-reviewed studies (e.g., SURPASS-4 showing 20% CVD risk reduction).

2. Reconsideration (Level 2):

   • If denied again, request an Independent Review Entity (IRE) review via Maximus Federal Services.
   • Success rate: ~40% of denials are overturned at this stage.

3. Administrative Law Judge (ALJ) Hearing (Level 3):

   • For denials involving ≥$180 in dispute, request a hearing with an ALJ (average wait time: 6–12 months).
   • Success rate: ~50%, especially with strong clinical evidence.

4. Medicare Appeals Council (Level 4) and Federal Court (Level 5):

   • Rarely pursued due to time and cost, but viable for high-stakes cases (e.g., Zepbound as a last-line therapy before insulin).

Alternative options if appeals fail:

• Manufacturer assistance: Apply for Lilly Cares Foundation (income-based).
• Clinical trials: Enroll in Zepbound studies (e.g., SURMOUNT-MMO for metabolic syndrome).
• State pharmaceutical assistance programs (SPAPs): Some states (e.g., New York, Pennsylvania) offer copay assistance for Medicare beneficiaries.

Medicare Alternatives If Zepbound Is Not Covered

If Zepbound is denied or unaffordable, consider these evidence-based alternatives:

1. GLP-1 agonists (covered for diabetes):

   • Ozempic (semaglutide): Medicare covers it for diabetes; ~$300–$500/month with Part D.
   • Mounjaro (tirzepatide): Identical to Zepbound but only FDA-approved for diabetes; may be covered if Zepbound is denied.
   • Victoza (liraglutide): Lower cost (~$150–$300/month) but less effective for weight loss.

2. SGLT2 inhibitors (covered for diabetes/CVD):

   • Jardiance (empagliflozin): Reduces CVD mortality by 38% (EMPA-REG OUTCOME trial).
   • Farxiga (dapagliflozin): Approved for heart failure and CKD.

3. Compounded tirzepatide:

   • 503A/503B pharmacies (e.g., Honeybee Health, CoreRx) offer compounded tirzepatide for $200–$400/month.
   • Caution: FDA warns about unregulated compounding; ensure USP-grade ingredients.

4. Lifestyle interventions (covered by Medicare):

   • Intensive Behavioral Therapy (IBT) for Obesity: Medicare covers 15-minute visits with a primary care provider for BMI ≥30.
   • Medical Nutrition Therapy (MNT): Registered dietitians provide 3 hours of counseling/year for diabetes.

5. Bariatric surgery (covered for BMI ≥35 with comorbidities):

   • Medicare covers **gastric bypass